Hyperphosphorylation of sarcomeric proteins in heart failure with preserved ejection fraction: selective reversal of PKC hyperactivity by cell therapy

ABSTRACT: Phosphorylation of sarcomeric proteins has been implicated in heart failure with preserved ejection fraction (HFpEF); such changes may contribute to diastolic dysfunction by altering contractility, cardiac stiffness, Ca2+-sensitivity and mechanosensing. Treatment with cardiosphere-derived cells (CDCs) restores normal diastolic function, attenuates fibrosis and inflammation, and improves survival in a rat HFpEF model. Here, we quantified the phosphorylation changes that underlie HFpEF and those reversed by CDC therapy, with a focus on the sarcomeric subproteome.

INSTRUMENT(S):

ORGANISM(S): Rattus Norvegicus (rat)

TISSUE(S): Heart, Heart Left Ventricle

DISEASE(S): Cardiovascular System Disease

SUBMITTER: Vidya Venkatraman  

LAB HEAD: Dr. Jennifer Van Eyk

PROVIDER: PXD025555 | Pride | 2022-04-23

REPOSITORIES: Pride